The is a landmark document in the biopharmaceutical industry, serving as a comprehensive blueprint for applying Quality by Design (QbD) principles to monoclonal antibody (mAb) development . Published in 2009 by the CMC Biotech Working Group , it remains a primary educational resource for understanding how to integrate regulatory guidelines (ICH Q8, Q9, and Q10) into real-world manufacturing. Key Takeaways & Core Concepts
Focuses on cell culture optimization, including host cell line characterization and risk assessments for process parameters such as pH, dissolved oxygen, and initial cell density. Downstream Recovery and Purification: A Mab A Case Study In Bioprocess Development
: Parameters like pH, dissolved oxygen, and initial viable cell density (iVCD) are studied in bioreactors to optimize growth and titer. The is a landmark document in the biopharmaceutical
It outlines a systematic approach to identifying which product attributes (like glycosylation or aggregation) significantly impact safety and efficacy. Upstream Manufacturing Development: Downstream Recovery and Purification: : Parameters like pH,
Proposes methods for real-time release testing and lifecycle management to maintain consistent quality throughout commercial manufacturing. Relevant Resources Quality By Design for Monoclonal Antibodies, Part 1